Cargando…

Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period

Reports of neuro-ophthalmological manifestations and complications in patients with coronavirus disease 19 (COVID-19) are still scarce. The aim of this article is to present optic neuritis, as possible post-infectious manifestation of COVID-19. Four weeks after hospitalization for seropositive coron...

Descripción completa

Detalles Bibliográficos
Autores principales: Žorić, Lepša, Rajović-Mrkić, Isidora, Čolak, Emina, Mirić, Dijana, Kisić, Bojana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165557/
https://www.ncbi.nlm.nih.gov/pubmed/34079389
http://dx.doi.org/10.2147/IMCRJ.S315103
_version_ 1783701347287171072
author Žorić, Lepša
Rajović-Mrkić, Isidora
Čolak, Emina
Mirić, Dijana
Kisić, Bojana
author_facet Žorić, Lepša
Rajović-Mrkić, Isidora
Čolak, Emina
Mirić, Dijana
Kisić, Bojana
author_sort Žorić, Lepša
collection PubMed
description Reports of neuro-ophthalmological manifestations and complications in patients with coronavirus disease 19 (COVID-19) are still scarce. The aim of this article is to present optic neuritis, as possible post-infectious manifestation of COVID-19. Four weeks after hospitalization for seropositive coronavirus disease 19 (COVID-19), presented as bilateral bronchopneumonia, with radiology and laboratory findings also pointed to high clinical suspicion to COVID-19, a 63-year-old man developed a headache and subacute and profound visual loss on his right eye. The disease presentation was the right eye papillitis. Inflammatory parameters were normal at the time of hospitalization, and IgM and IgG for SARS-CoV-2 were still positive. After corticosteroid pulse therapy, his vision improved significantly and on follow-up visits returned to normal. All laboratory and radiology findings were unremarkable, except for antibodies against SARS-CoV-2 and myelin oligodendrocyte glycoprotein (MOG). We discuss about capacity of SARS-CoV-2 to cause optic neuritis and possible significance of MOG antibodies in similar cases.
format Online
Article
Text
id pubmed-8165557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81655572021-06-01 Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period Žorić, Lepša Rajović-Mrkić, Isidora Čolak, Emina Mirić, Dijana Kisić, Bojana Int Med Case Rep J Case Report Reports of neuro-ophthalmological manifestations and complications in patients with coronavirus disease 19 (COVID-19) are still scarce. The aim of this article is to present optic neuritis, as possible post-infectious manifestation of COVID-19. Four weeks after hospitalization for seropositive coronavirus disease 19 (COVID-19), presented as bilateral bronchopneumonia, with radiology and laboratory findings also pointed to high clinical suspicion to COVID-19, a 63-year-old man developed a headache and subacute and profound visual loss on his right eye. The disease presentation was the right eye papillitis. Inflammatory parameters were normal at the time of hospitalization, and IgM and IgG for SARS-CoV-2 were still positive. After corticosteroid pulse therapy, his vision improved significantly and on follow-up visits returned to normal. All laboratory and radiology findings were unremarkable, except for antibodies against SARS-CoV-2 and myelin oligodendrocyte glycoprotein (MOG). We discuss about capacity of SARS-CoV-2 to cause optic neuritis and possible significance of MOG antibodies in similar cases. Dove 2021-05-25 /pmc/articles/PMC8165557/ /pubmed/34079389 http://dx.doi.org/10.2147/IMCRJ.S315103 Text en © 2021 Žorić et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Report
Žorić, Lepša
Rajović-Mrkić, Isidora
Čolak, Emina
Mirić, Dijana
Kisić, Bojana
Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period
title Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period
title_full Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period
title_fullStr Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period
title_full_unstemmed Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period
title_short Optic Neuritis in a Patient with Seropositive Myelin Oligodendrocyte Glycoprotein Antibody During the Post-COVID-19 Period
title_sort optic neuritis in a patient with seropositive myelin oligodendrocyte glycoprotein antibody during the post-covid-19 period
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165557/
https://www.ncbi.nlm.nih.gov/pubmed/34079389
http://dx.doi.org/10.2147/IMCRJ.S315103
work_keys_str_mv AT zoriclepsa opticneuritisinapatientwithseropositivemyelinoligodendrocyteglycoproteinantibodyduringthepostcovid19period
AT rajovicmrkicisidora opticneuritisinapatientwithseropositivemyelinoligodendrocyteglycoproteinantibodyduringthepostcovid19period
AT colakemina opticneuritisinapatientwithseropositivemyelinoligodendrocyteglycoproteinantibodyduringthepostcovid19period
AT miricdijana opticneuritisinapatientwithseropositivemyelinoligodendrocyteglycoproteinantibodyduringthepostcovid19period
AT kisicbojana opticneuritisinapatientwithseropositivemyelinoligodendrocyteglycoproteinantibodyduringthepostcovid19period